EMA aims to spark debate on quality in clinical trials

By Gareth Macdonald

- Last updated on GMT

Related tags Risk Contract research organization Management

The EMA says current GCP rules make quality management in trials too costly and need to be revised into a code that meets the needs of academics, small and midsized drugmakers and Big Pharmas alike.

The agency made the comments in a reflection paper​ in which it argues that the relevant regulations - ICH GCP Section 5.1​ on sponsors’ implementation of quality systems and Article 2 of GCP Directive 2005/28/EC​, which sets out the monitoring procedures necessary - are no longer fit for purpose.

Current practices are not proportionate or well adapted to achieving the desired goals and are generally very costly, resulting either in success at an unnecessarily high cost or failure which is also very costly​.”

Instead, the European Medicines Agency (EMA) proposes that academics, pharmas and contract research organisations (CROs) start thinking about new approaches to ensuring quality in clinical trials and suggests that the definition of the word itself may be a good place to start.

Simply advocating the ‘highest level’ of quality has little meaning in itself​,” it says, adding that “the cost associated with incremental improvements in quality becomes ever higher as perfection is approached and becomes disproportionate to any additional benefit achieved​.”

The agency suggests instead that data and information quality should be defined in terms of suitability for decision making which, in the research context, effectively means whether or not the drug under assessment continues to be developed.

Risk-based quality management

The EMA goes on to describe what it calls a ‘risk based approach to quality management​,’ which involves sponsors and CROs monitoring and identifying risk continuously throughout the development, execution and analysis of a trial.

The principles of risk management and the overview of the process as outlined in ICH Q9 apply as much to clinical trials as to other areas​,” it says, adding that the application of this approach to trials could “facilitate better and more informed decision making and make the most of available resources​.”

The EMA is seeking feedback for its proposals from the contract research sector, the closing date for which is February 15, 2012.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more